Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Livzon Mabpharm, Inc.

https://en.livzon.com.cn/

Latest From Livzon Mabpharm, Inc.

China Taps Roche Antibody, Green Lights Testing Kits For Coronavirus Arsenal

Kicking a rapid response mechanism into full gear, China approves Roche’s Actemra as a new treatment for coronavirus along with a flurry of testing kits.

China Infectious Diseases

Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike

VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.

Financing StartUps and SMEs

Amgen & Simcere Plot Long Run On Biosimilars In China

The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city last week, amid heightened excitement around China’s newly issued opinions on deepening reforms to encourage drug innovation including biosimilars. With the favorable opportunities, Amgen is open to establishing more local partnerships as its core China strategy.

China Biosimilars

Amgen & Simcere Plot Long Run On Biosimilars In China

The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city last week, amid heightened excitement around China’s newly issued opinions on deepening reforms to encourage drug innovation including biosimilars. With the favorable opportunities, Amgen is open to establishing more local partnerships as its core China strategy.

China Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Livzon Pharmaceutical Group Inc.
UsernamePublicRestriction

Register